Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for PaxMedica's Net Cash per Share or its related term are showing as below:
PXMD's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.915 * Ranked among companies with meaningful Price-to-Net-Cash only.
PaxMedica (OTCPK:PXMD) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
PaxMedica Net Cash per Share Related Terms
PaxMedica Net Cash per Share Historical Data
* Premium members only.
The historical data trend for PaxMedica's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PXMD vs BTAX, NBIO, ARTHQ: Net Cash per Share Comparison
For the Biotechnology subindustry, PaxMedica's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PaxMedica Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, PaxMedica's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where PaxMedica's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
PaxMedica's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PaxMedica (PXMD) has a Net Cash per Share of $-0.21 as of Sep. 2024. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on PaxMedica and its competitors.
Is PaxMedica's Net Cash per Share too high?
PaxMedica's current Net Cash per Share is $-0.21.
How does PaxMedica's Net Cash per Share compare to BTAX and NBIO?
PaxMedica's Net Cash per Share of $-0.21 can be compared against companies in the Biotechnology industry. The industry median Net Cash per Share is 4.92. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 4.92, based on 772 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on PaxMedica and its competitors. For the Biotechnology industry, the median Net Cash per Share is 4.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PaxMedica's current Net Cash per Share is $-0.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PaxMedica stock overvalued right now?
PaxMedica (PXMD) has a current Net Cash per Share of $-0.21. The current Net Cash per Share is $-0.21. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For PaxMedica (PXMD), the current Net Cash per Share is $-0.21 as of Sep. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PaxMedica Inc is a clinical-stage biopharmaceutical company focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and now with rising incidence globally due to the long term effects of SARS-CoV-2 (COVID-19). The company's product candidate under development is PAX-101, an intravenous formulation of suramin, which it is developing for multiple indications, including East African HAT, ASD, ME/CFS, and LCS.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PXMD has been successfully added to your 
